FDA Inspection 1269495 — Evonik Rexim (Nanning) Pharmaceutical Co. Ltd.
The FDA completed an inspection of Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. on April 11, 2025 in Nanning. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 11, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nanning (China)